Mild B-cell lymphocytosis in patients with a CARD11 C49Y mutation - 04/09/15
Doi : 10.1016/j.jaci.2015.03.008
David Buchbinder, MD a, b, ∗, Jeffrey R. Stinson, MS c, ∗, Diane J. Nugent, MD a, b, Lucie Heurtier, MSc d, e, Felipe Suarez, MD, PhD d, f, Gauthaman Sukumar, PhD g, Clifton L. Dalgard, PhD g, Cécile Masson, MSc h, Mélanie Parisot, BSc i, Yu Zhang, PhD j, Helen F. Matthews, RN j, Helen C. Su, MD, PhD j, Anne Durandy, MD, PhD d, e, Alain Fischer, MD, PhD d, e, k, l, Sven Kracker, PhD d, e 
, Andrew L. Snow, PhD c
, Andrew L. Snow, PhD c a Department of Hematology, Children's Hospital of Orange County, Orange, Calif
b Department of Pediatrics, University of California at Irvine, Orange, Calif
c Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Md
d Université Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France
e INSERM UMR 1163, Human Lymphohematopoiesis Laboratory, Paris, France
f Service d’Hématologie Adultes, Hôpital Necker-Enfants Malades, Paris, France
g Department of Anatomy, Physiology, & Genetics, Uniformed Services University of the Health Sciences, Bethesda, Md
h Bioinformatic Platform, Université Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France
i Genomic Core Facility, Université Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France
j Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
k Department of Pediatric Immunology, Hematology and Rheumatology, Hôpital Necker Enfants Malades, Paris, France
l Collège de France, Paris, France
| J.R.S. and A.L.S. were supported by grants from the Concern Foundation and the Uniformed Services University. Y.Z. and H.C.S. were supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. L.H., A.D., A.F., and S.K. were supported by the “Institut national de la santé et de la recherche médicale,” the European Union's 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE contract 249816), the Fondation pour la Recherche Médicale (grant no. ING20130526624), la Ligue Contre le Cancer (Comité de Paris), and a government grant managed by the French Agence Nationale de la Recherche as part of the “Investments for the Future” program (grant no. ANR-10-IAHU-01). S.K. is a Centre National de la Recherche Scientifique (CNRS) researcher. |
|
| Disclosure of potential conflict of interest: A. Fischer has been supported by ERC advanced grant PID-IMMUNE contract 249816 and ANR-10-IAHU-01. S. Kracker has received research support from Fondation pour la Recherche Médicale (grant no. ING20130526624), la Ligue Contre le Cancer (Comité de Paris), and the “Investments for the Future” program (grant no. ANR-10-IAHU-01). A. L. Snow has received travel support from the Novartis Institutes for Biomedical Research. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2015
Publié par Elsevier Masson SAS.
Vol 136 - N° 3
P. 819 - septembre 2015 Retour au numéro
Article précédent
- A novel hypomorphic mutation in STIM1 results in a late-onset immunodeficiency
- Heidi Schaballie, Rémy Rodriguez, Emmanuel Martin, Leen Moens, Glynis Frans, Christelle Lenoir, Joris Dutré, Danielle Canioni, Xavier Bossuyt, Alain Fischer, Sylvain Latour, Isabelle Meyts, Capucine Picard
- Look before you LEAP: Risk of anaphylaxis in high-risk infants with early introduction of peanut
- Nathan Rabinovitch, Dimple Shah, Bruce J. Lanser
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?